aTyr Pharma, Inc.(US:ATYR) Globenewswire·2025-12-03 21:21Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the efficacy of its drug Efzofitimod, which led to a significant drop in stock price after disappointing study results were announced [3][4]. Group 1: Allegations and Impact - The class period for the lawsuit is from November 7, 2024, to September 12, 2025 [3]. - The complaint alleges that aTyr Pharma made overwhelmingly positive statements while concealing material adverse facts about Efzofitimod's efficacy, particularly its ability to allow patients to taper steroid usage completely [3]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to an 83.2% decline in stock price from $6.03 to $1.02 per share in one day [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action lawsuit by December 8, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for shareholders [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].